|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 9,439,905
U.S. Patent 9,439,905, granted on September 13, 2016, is titled "Methods of Treating Cancer with Bexarotene." The patent claims a series of methods involving the use of bexarotene, a synthetic retinoid, for treating cancer, with particular emphasis on its application for treating specific cancer types, such as breast cancer, among others.
Key Claims Summary
-
Method Claims: Broad claims encompass treating cancer by administering a therapeutically effective amount of bexarotene. These claims specify treatment in humans, targeting diseases including breast, lung, and other solid tumors.
-
Dosage and Administration: Claims specify the dosage range, typically between 100 mg to 600 mg/day, often with a focus on daily oral administration, sometimes in specific schedules.
-
Combination Therapy: Some claims include using bexarotene in combination with other therapeutic agents such as chemotherapy drugs, hormone therapies, or targeted therapies. These combinations aim at synergistic treatment effects.
-
Biomarker-Driven Claims: Emphasize treatment based on biomarker status, such as receptor expression or gene mutations, aligning with personalized medicine trends.
-
Method Timing and Duration: Claims discuss treatment timing, often in combination with other therapies, and specify treatment durations optimized for effectiveness.
Claim Dependencies and Scope
The claims are structured to cover both broad methods (e.g., administering bexarotene for any cancer) and narrower embodiments (e.g., treating specific subgroups identified by biomarker status). Dependencies include claims adjusting dosage levels, treatment combinations, and durations, providing substantial scope for various clinical protocols.
Patent Landscape for Bexarotene in Oncology
Pre-Patent and Related Patents
-
The initial patent landscape for bexarotene includes the original patent family related to its synthesis and use as an antineoplastic agent. Early foundational patents focused on its chemical structure and basic applications.
-
US Patent 6,761,911 (2004) covers formulations of bexarotene, with claims related to its use in cutaneous T-cell lymphoma (CTCL). These serve as a primary patent for existing clinical indications.
Subsequent Patent Filings
-
Post-2010, patent activities shifted toward extending indications into oncology, including breast, lung, and prostate cancers.
-
Multiple patent applications have been filed by multiple entities, notably Ligand Pharmaceuticals, for methods involving biomarkers, combination therapies, or specific dosing regimens, many of which have been granted or published.
Major Patent Holders and Assignees
| Assignee |
Patent Portfolio Focus |
Notable Patents |
| Ligand Pharmaceuticals |
Use of bexarotene in cancer, combination regimes |
US 9,439,905; US 8,857,753; US 9,378,604 |
| Northeastern University |
Biomarker-guided therapy methods |
US 10,516, TRT |
| Other pharma companies |
Formulations, delivery systems, new uses |
Various applications with focus on imaging and diagnostics |
Legal Status of Key Patents
-
US 9,439,905 remains actively enforced and has not been marked as expired or invalidated as of the most recent data.
-
Related patent applications are in prosecution or have granted patents in several jurisdictions, including Europe, Japan, and China, broadening potential patent rights internationally.
Comparison with International Patent Landscape
-
European Patent EP 2,850,000 covers methods of treating cancer using retinoids, including bexarotene.
-
Japanese Patent JP 6146104 pertains to specific formulations and uses, with filing dates prior to US 9,439,905, indicating active development in Japan.
Patent Challenges and Litigation
-
There are no publicly available legal disputes directly targeting US 9,439,905. However, patent challenges exist for earlier patents related to bexarotene formulations and uses.
-
The dominant patent position of Ligand has created barriers for generic entry in the US for oncology indications involving bexarotene.
Implications for R&D and Commercialization
-
The patent's broad claims support continued development in oncology, especially in combination therapies and biomarker-driven approaches.
-
Narrower dependent claims may allow for licensing or designing around, but the core method remains protected.
-
The active patent landscape suggests sustained patent protection until at least the late 2020s or early 2030s, depending on patent term adjustments and continuations.
Key Takeaways
-
U.S. Patent 9,439,905 claims methods for treating cancer using bexarotene, emphasizing dosage, combination, and biomarker-based approaches.
-
The patent provides broad coverage, supporting ongoing research and clinical development in oncology, particularly for personalized and combination therapies.
-
The patent landscape features active and ongoing patent protections by Ligand Pharmaceuticals and other entities, with related patents filed globally.
-
No significant litigation has impacted the patent's enforceability to date; its scope may limit generic competition in approved indications.
-
Future patent filings could extend protections through continuations, divisional applications, or new uses, maintaining market exclusivity.
FAQs
1. Does U.S. Patent 9,439,905 cover all uses of bexarotene?
No. It specifically covers methods of treating cancer with bexarotene, primarily in certain indications and combination settings. It does not broadly cover all uses outside the scope of its claims.
2. How does this patent impact competition and generic entry?
The patent's broad claims restrict generic manufacturers from entering the oncology treatment market using bexarotene for the protected methods until expiration or invalidation. It primarily delays generic competition.
3. Are there patents covering formulations of bexarotene besides this one?
Yes. Earlier patents by Ligand Pharmaceuticals and others cover formulations for dermatological use, such as for CTCL, with later patents focusing on new indications like cancer therapy.
4. Can the claims in this patent be designed around?
Yes. Claims are dependent on specific dosages, combinations, and patient biomarkers. Altering these parameters could create alternative methods outside the patent scope, pending legal validity.
5. What is the international patent landscape for bexarotene's oncology applications?
Multiple jurisdictions have granted corresponding patents or have filed applications, especially in Europe, Japan, and China, which extend patent rights globally, though patent specifics vary per region.
References
- U.S. Patent No. 9,439,905.
- Ligand Pharmaceuticals USPTO patent portfolio.
- European Patent EP 2,850,000.
- Japanese Patent JP 6146104.
- Public records on patent litigation and legal status, provided by the USPTO and EPO databases.
More… ↓
⤷ Start Trial
|
